Ustekinumab (UST) is a recently approved drug for the treatment of psoriatic arthritis (PsA). The ACR response rates in randomized clinical trials (RCTs) with this drug have been slightly lower than that reported in RCTs of anti-TNF and anti-IL17 therapies. Therefore, the position that this drug may occupy in the treatment algorithms of PsA is not clear. More information is needed on the true efficacy of this agent under real clinical practice conditions. In this review of real-world evidence studies, it is shown that UST is effective and safe to treat PsA; nevertheless, it is necessary to homogenize the way in which the main outcomes and treatment objectives of these studies are presented.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14712598.2018.1504919 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Two rashes, one patient: Enfortumab vedotin-induced interface dermatitis and pembrolizumab-induced psoriatic disease treated with ixekizumab.
JAAD Case Rep
November 2024
Department of Dermatology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Correction: Physical component of SF-36 is associated with measures of disease activity in patients with psoriatic arthritis: a real-life study from a tertiary referral centre.
Rheumatol Int
January 2025
Department of Rheumatology, Physical and Rehabilitation medicine Sestre milosrdnice, University Hospital Center, Zagreb, Croatia.
Transition-related outcomes among a cohort of patients with juvenile idiopathic arthritis.
Clin Rheumatol
January 2025
University of Trieste, Trieste, Italy.
A major goal in juvenile idiopathic arthritis (JIA) long-term management is to ensure a successful transition to adult age. This study aims to assess transition outcomes in a group of JIA patients during their passage from pediatric to adult healthcare assistance at a single center. This is a cross-sectional study.
View Article and Find Full Text PDFRORγt inverse agonists demonstrating a margin between inhibition of IL-17A and thymocyte apoptosis.
PLoS One
January 2025
Bioscience COPD/IPF, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Multiple genetic associations suggest a causative relationship between Th17-related genes coding for proteins, such as IL-17A, IL-23 and STAT3, and psoriasis. Further support for this link comes from the findings that neutralizing antibodies directed against IL-17A, IL-17RA and IL-23 are efficacious in diseases like psoriasis, psoriatic arthritis and ankylosing spondylitis. RORγt is a centrally positioned transcription factor driving Th17 polarization and cytokine secretion and modulation of RORγt may thus provide additional benefit to patients.
View Article and Find Full Text PDFAssociation between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis.
J Rheumatol
January 2025
Laura C Coates BM BCh PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Objective: The aim of this analysis was to evaluate the relationship between the criteria met of the Minimal Disease Activity (MDA) score for psoriatic arthritis (PsA) and patient-perceived disease status.
Methods: We analysed data from the ReFlaP study (NCT03119805), a cross-sectional international study of adult patients with PsA. Patients self-reported if they felt their PsA was in remission (REM), low disease activity (LDA) or neither.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!